Financhill
Buy
57

LLY Quote, Financials, Valuation and Earnings

Last price:
$714.99
Seasonality move :
3.04%
Day range:
$711.55 - $722.19
52-week range:
$677.09 - $972.53
Dividend yield:
0.77%
P/E ratio:
58.99x
P/S ratio:
13.36x
P/B ratio:
41.28x
Volume:
4M
Avg. volume:
4.8M
1-year change:
-10.92%
Market cap:
$650.8B
Revenue:
$45B
EPS (TTM):
$12.29

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LLY
Eli Lilly and
$12.7B $3.46 26.74% 68.13% $966.01
AMGN
Amgen
$8B $4.26 5.5% 281.73% $314.20
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $46.66
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $797.21
VKTX
Viking Therapeutics
-- -$0.31 -- -120.34% $90.26
VRTX
Vertex Pharmaceuticals
$2.9B $4.29 9.83% 1.98% $500.30
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LLY
Eli Lilly and
$724.95 $966.01 $650.8B 58.99x $1.50 0.77% 13.36x
AMGN
Amgen
$271.90 $314.20 $146.2B 24.81x $2.38 3.41% 4.31x
MRNA
Moderna
$25.80 $46.66 $10B -- $0.00 0% 3.20x
REGN
Regeneron Pharmaceuticals
$604.62 $797.21 $65.3B 15.39x $0.88 0.29% 4.90x
VKTX
Viking Therapeutics
$27.25 $90.26 $3.1B -- $0.00 0% --
VRTX
Vertex Pharmaceuticals
$435.32 $500.30 $111.8B 26.10x $0.00 0% 10.16x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
MRNA
Moderna
-- 0.406 -- 3.92x
REGN
Regeneron Pharmaceuticals
6.33% 0.973 2.89% 3.90x
VKTX
Viking Therapeutics
-- -0.956 -- --
VRTX
Vertex Pharmaceuticals
-- 0.843 -- 2.12x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M
VRTX
Vertex Pharmaceuticals
$2.4B $1B -6.04% -6.04% 26.48% $778.2M

Eli Lilly and vs. Competitors

  • Which has Higher Returns LLY or AMGN?

    Amgen has a net margin of 21.68% compared to Eli Lilly and's net margin of 21.23%. Eli Lilly and's return on equity of 78.25% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About LLY or AMGN?

    Eli Lilly and has a consensus price target of $966.01, signalling upside risk potential of 33.25%. On the other hand Amgen has an analysts' consensus of $314.20 which suggests that it could grow by 15.56%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 5 1
    AMGN
    Amgen
    10 14 2
  • Is LLY or AMGN More Risky?

    Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock LLY or AMGN?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.77%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.38 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios LLY or AMGN?

    Eli Lilly and quarterly revenues are $12.7B, which are larger than Amgen quarterly revenues of $8.1B. Eli Lilly and's net income of $2.8B is higher than Amgen's net income of $1.7B. Notably, Eli Lilly and's price-to-earnings ratio is 58.99x while Amgen's PE ratio is 24.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 13.36x versus 4.31x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    13.36x 58.99x $12.7B $2.8B
    AMGN
    Amgen
    4.31x 24.81x $8.1B $1.7B
  • Which has Higher Returns LLY or MRNA?

    Moderna has a net margin of 21.68% compared to Eli Lilly and's net margin of -907.48%. Eli Lilly and's return on equity of 78.25% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About LLY or MRNA?

    Eli Lilly and has a consensus price target of $966.01, signalling upside risk potential of 33.25%. On the other hand Moderna has an analysts' consensus of $46.66 which suggests that it could grow by 80.84%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 5 1
    MRNA
    Moderna
    5 17 1
  • Is LLY or MRNA More Risky?

    Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

  • Which is a Better Dividend Stock LLY or MRNA?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.77%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or MRNA?

    Eli Lilly and quarterly revenues are $12.7B, which are larger than Moderna quarterly revenues of $107M. Eli Lilly and's net income of $2.8B is higher than Moderna's net income of -$971M. Notably, Eli Lilly and's price-to-earnings ratio is 58.99x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 13.36x versus 3.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    13.36x 58.99x $12.7B $2.8B
    MRNA
    Moderna
    3.20x -- $107M -$971M
  • Which has Higher Returns LLY or REGN?

    Regeneron Pharmaceuticals has a net margin of 21.68% compared to Eli Lilly and's net margin of 26.7%. Eli Lilly and's return on equity of 78.25% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About LLY or REGN?

    Eli Lilly and has a consensus price target of $966.01, signalling upside risk potential of 33.25%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 31.85%. Given that Eli Lilly and has higher upside potential than Regeneron Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 5 1
    REGN
    Regeneron Pharmaceuticals
    14 4 0
  • Is LLY or REGN More Risky?

    Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

  • Which is a Better Dividend Stock LLY or REGN?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.77%. Regeneron Pharmaceuticals offers a yield of 0.29% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or REGN?

    Eli Lilly and quarterly revenues are $12.7B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Eli Lilly and's net income of $2.8B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Eli Lilly and's price-to-earnings ratio is 58.99x while Regeneron Pharmaceuticals's PE ratio is 15.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 13.36x versus 4.90x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    13.36x 58.99x $12.7B $2.8B
    REGN
    Regeneron Pharmaceuticals
    4.90x 15.39x $3B $808.7M
  • Which has Higher Returns LLY or VKTX?

    Viking Therapeutics has a net margin of 21.68% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 78.25% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About LLY or VKTX?

    Eli Lilly and has a consensus price target of $966.01, signalling upside risk potential of 33.25%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 231.24%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 5 1
    VKTX
    Viking Therapeutics
    10 2 0
  • Is LLY or VKTX More Risky?

    Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

  • Which is a Better Dividend Stock LLY or VKTX?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.77%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or VKTX?

    Eli Lilly and quarterly revenues are $12.7B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $2.8B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Eli Lilly and's price-to-earnings ratio is 58.99x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 13.36x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    13.36x 58.99x $12.7B $2.8B
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M
  • Which has Higher Returns LLY or VRTX?

    Vertex Pharmaceuticals has a net margin of 21.68% compared to Eli Lilly and's net margin of 23.33%. Eli Lilly and's return on equity of 78.25% beat Vertex Pharmaceuticals's return on equity of -6.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
    VRTX
    Vertex Pharmaceuticals
    86.9% $2.49 $16.5B
  • What do Analysts Say About LLY or VRTX?

    Eli Lilly and has a consensus price target of $966.01, signalling upside risk potential of 33.25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 14.93%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 5 1
    VRTX
    Vertex Pharmaceuticals
    14 14 1
  • Is LLY or VRTX More Risky?

    Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

  • Which is a Better Dividend Stock LLY or VRTX?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.77%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or VRTX?

    Eli Lilly and quarterly revenues are $12.7B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Eli Lilly and's net income of $2.8B is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, Eli Lilly and's price-to-earnings ratio is 58.99x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 13.36x versus 10.16x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    13.36x 58.99x $12.7B $2.8B
    VRTX
    Vertex Pharmaceuticals
    10.16x 26.10x $2.8B $646.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Why Did Forge Global Stock Go Down?
Why Did Forge Global Stock Go Down?

Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…

Is GlobalFoundries On The Verge Of A Breakout?
Is GlobalFoundries On The Verge Of A Breakout?

GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
WIX alert for May 22

Wix.com [WIX] is up 1.88% over the past day.

Buy
79
DY alert for May 23

Dycom Industries [DY] is down 0% over the past day.

Sell
50
FICO alert for May 23

Fair Isaac [FICO] is down 0.46% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock